Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Biogen Idec acquires Neurimmune subsidiary

Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.

21 Dec 2010

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Arrowhead Research Corporation today announced that it has executed an exclusive world-wide license on technology developed by Drs. Wadih Arap and Renata Pasqualini at MD Anderson Cancer Center for use in weight loss and obesity-related metabolic conditions, and that it has launched a new company, Ablaris Therapeutics Inc., to commercialize this platform.

20 Dec 2010

New communication toolkit could improve information and advice on emerging food risks

Improvements in the delivery of information and advice on emerging food risks could lead to fewer food-related illnesses, a reduction in economic losses related to food scares, and improved consumer confidence in foods.

20 Dec 2010

Patheon fourth quarter revenues increase 0.9% to $177.7 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the fourth quarter and full year ended October 31, 2010. Revenues for the fourth quarter were $177.7 million or 0.9 percent higher than the same period last year. Excluding currency fluctuations, current year fourth quarter revenues would have increased by approximately 5.0 percent versus the same period last year.

17 Dec 2010

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Novavax, Inc. announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

16 Dec 2010

Akonni receives $150,000 Phase I NSF grant to assess feasibility of developing lab-on-a-film microarray device

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated molecular testing devices for diagnosing infectious diseases and human genetic disorders, announced today the receipt of a $150,000 Phase I Grant from the National Science Foundation (NSF). This initial round of funding from NSF will enable Akonni to assess the feasibility of developing a lab-on-a-film microarray device that can be manufactured in a reel-to-reel format.

16 Dec 2010

Almac recognised with 'News Flow of the Year' award

The Almac Group, one of the world's leading contract drug development and manufacturing organisations, was presented with the "News Flow of the Year" accolade at the 2010 Genesis Awards annual Gala dinner in London last week, following the company being shortlisted as a finalist in the category nominations. Now into its tenth year, Genesis is established as a leading life science networking conference.

16 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Repligen Corporation today announced that the Company has received $1,400,000 in research funding from the Muscular Dystrophy Association ("MDA") to support the ongoing development of RG3039 for Spinal Muscular Atrophy ("SMA"). RG3039, our lead compound, is an inhibitor of an RNA processing enzyme which targets increased production of SMN, a protein of deficient levels in patients with SMA.

15 Dec 2010

Atrium acquires Belgium-based Minami Nutrition

Atrium Innovations Inc., a recognized leading developer, manufacturer and marketer of professionally endorsed, science-based dietary supplements for the health and nutrition industry, today announced the purchase of Belgium-based Minami Nutrition, a niche brand of superior quality scientifically proven Omega-3 products primarily sold in several European countries.

15 Dec 2010

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Profectus Biosciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today that its GENEVAX™ IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I clinical study of an experimental DNA vaccine for the prevention of HIV infection.

15 Dec 2010

DSM licenses c-LEcta's alcohol dehydrogenases for enzyme screening programs

DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, today announces a license agreement with c-LEcta GmbH for proprietary screening technology.

15 Dec 2010

China Nuokang receives SFDA manufacturing license for Dipyridamole Aspirin

China Nuokang Bio-Pharmaceutical Inc., a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company has received the manufacturing license from the State Food and Drug Administration ("SFDA") for Dipyridamole Aspirin, a stroke-prevention product developed in-house.

15 Dec 2010

Bohai to acquire rights to 14 approved Traditional Chinese Medicines for $7,200,000

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM), has entered into a binding agreement with Shandong Daxin Microbiology Pharmaceutical Industry Co., Ltd. to acquire the rights to 14 approved TCM medicines that were previously issued to Daxin by the Shandong Branch of the State Food and Drug Administration of China ("SFDA").

14 Dec 2010

Natural Prosthetic Dental Lab launches 'Digital revolution of dentistry'

News briefs concerning economic and business growth in the Tampa Bay region from the Tampa Bay Partnership:

14 Dec 2010

ProJect Pharmaceutics opens laboratory facilities in Martinsried, Munich

ProJect Pharmaceutics started business operations and opened its laboratory facilities in the Biotech-cluster in Martinsried, near Munich. ProJect Pharmaceutics transforms proteins, peptides and delicate small molecules into pioneering drugs.

14 Dec 2010

ONC enters exclusive long term strategic agreement with Wilmar

Ocean Nutrition Canada Limited (ONC), the world's largest Omega-3 EPA/DHA solutions provider, and supplier of MEG-3® brand Omega-3 EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) ingredients, is pleased to announce that it has entered into an exclusive long term strategic agreement with Wilmar International Limited (Wilmar), based in Singapore.

14 Dec 2010

Panasonic to manufacture electronic lenses for PixelOptics' electronic focusing eyeglasses

PixelOptics of Roanoke, Virginia USA announced today that Panasonic Healthcare Co., Ltd. of Ehime, Japan will manufacture electronic lenses for PixelOptics' electronic focusing eyeglasses named emPower!™. The emPower! eyeglasses focus faster than the blink of an eye, have no moving parts, and change focus without making a sound. In March of 2010 at Vision Expo East in New York, New York, Pixel and Panasonic announced that they have been working together for the last two plus years to develop and optimize Pixel's electronic lenses.

From PHC Europe B.V. 13 Dec 2010

CEL-SCI reports net income of $10.48M for fiscal 2010 vs. $40.9M loss for fiscal 2009

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2010.

13 Dec 2010

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.

13 Dec 2010

Manufacturing News and Research

Further Reading

Biogen Idec acquires Neurimmune subsidiary

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

New communication toolkit could improve information and advice on emerging food risks

Patheon fourth quarter revenues increase 0.9% to $177.7 million

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Akonni receives $150,000 Phase I NSF grant to assess feasibility of developing lab-on-a-film microarray device

Almac recognised with 'News Flow of the Year' award

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Atrium acquires Belgium-based Minami Nutrition

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

DSM licenses c-LEcta's alcohol dehydrogenases for enzyme screening programs

China Nuokang receives SFDA manufacturing license for Dipyridamole Aspirin

Bohai to acquire rights to 14 approved Traditional Chinese Medicines for $7,200,000

Natural Prosthetic Dental Lab launches 'Digital revolution of dentistry'

ProJect Pharmaceutics opens laboratory facilities in Martinsried, Munich

ONC enters exclusive long term strategic agreement with Wilmar

Panasonic to manufacture electronic lenses for PixelOptics' electronic focusing eyeglasses

CEL-SCI reports net income of $10.48M for fiscal 2010 vs. $40.9M loss for fiscal 2009

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News